��«����Ƶ

You’re judged by the company you keep.

That’s why we started collaborating with and Novo Nordisk to connect our world-leading with their world-class insulin delivery systems, including Bigfoot’s user-friendly systems intended to optimize insulin delivery as well as Novo Nordisk’s connected insulin pens.

And it’s why we’re now joining forces with to integrate FreeStyle Libre technology with Sanofi’s insulin dosing information for future smart pens, insulin titration apps and cloud software.

It’s a good group, this network of diabetes care experts. And we all have one big goal in common: The commitment to employing life-changing technology to make diabetes management as simple, easy and effective as it can be.

“Diabetes can be overwhelming. It’s an information-rich condition with various streams of data from multiple devices,” said Jared Watkin, senior vice president, Diabetes Care, ��«����Ƶ. ��“Building a digital ecosystem around FreeStyle Libre simplifies the user experience by consolidating how people get their data — both through offering ��«����Ƶ’s digital health tools and by working with other diabetes and technology leaders.”

Those tools include connected apps, FreeStyle LibreLink (which helps you monitor your glucose via a smartphone) as well as (which allows your loved ones to view your results after you scan).

With Sanofi on board, it’s a bigger digital healthcare ecosystem where information and data will be designed to share between FreeStyle Libre and our partner’s digital health tools, offering users personalized care.

As the world leader in sensor-based glucose monitoring, the FreeStyle Libre system is improving the lives of more than 1.5 million people.¹ With these partnerships, we’ll be able to improve the lives of millions more as they manage their condition.

These are connected device experiences that are connecting people with better care.

It’s what friends are for.

��

¹Data on file, ��«����Ƶ Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.